Controlled-Release Opioid Antagonist Composition for Urinary Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of specific treatment options for opioid-induced urinary retention, particularly in oral dosage forms, which poses a challenge in managing this condition effectively.
Innovation Solution
A pharmaceutical composition comprising an opioid antagonist, such as naloxone, and an opioid agonist, such as oxycodone, in a controlled release formulation to treat urinary retention, including opioid-induced cases, providing both immediate and sustained release properties to address the condition effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If intravenous opioid antagonists (methylnaltrexone, naloxone) are used to reverse opioid-induced bladder dysfunction, then urinary retention is treated, but the treatment is limited to intravenous administration and lacks oral dosage forms
Solution Approach 1:
The invention changes the administration route parameter from intravenous to oral, and introduces controlled-release formulation parameters to extend duration of action. This allows the same therapeutic agent (opioid antagonist) to be delivered through different routes and formulations, making the treatment more versatile and easier to administer while maintaining therapeutic efficacy
Solution Approach 2:
The invention segments the treatment approach by combining immediate-release and controlled-release formulations of opioid antagonists. This segmentation allows for both rapid onset (immediate-release) and sustained effect (controlled-release), providing flexibility in treating different stages and severities of opioid-induced urinary retention
2Object-affected harmful factors
If opioid agonists are administered for pain management, then pain is relieved, but urinary retention occurs as a side effect
Solution Approach 1:
The invention introduces an intermediary substance (opioid antagonist) that specifically counteracts the harmful effect (urinary retention) caused by the opioid agonist, while allowing the beneficial effect (pain relief) to continue. The antagonist acts as a mediator that selectively blocks the antagonist receptors responsible for urinary retention without completely blocking the agonist's pain-relieving effects
Solution Approach 2:
The invention converts the harmful side effect (urinary retention caused by opioid agonists) into a treatable condition with a specific counter-agent. By developing controlled-release formulations of opioid antagonists, the harm is transformed into a manageable situation where the antagonist's blocking effect is sustained over time, preventing urinary retention while preserving pain relief
3Reliability
If frequent administration of opioid antagonists is performed, then urinary retention is effectively treated, but patient compliance decreases and treatment complexity increases
Solution Approach 1:
The invention implements controlled-release formulations that provide continuous release of the opioid antagonist over extended periods (12-48 hours or longer). This continuity of useful action maintains therapeutic levels of the antagonist in the body, effectively treating urinary retention without requiring frequent dosing, thereby improving patient compliance while maintaining treatment reliability
Data Source
AI summary
The invention pertains to the use of opioid antagonists for the treatment of urinary retention.